IPP Bureau
Aerogen opens India HQ in New Delhi
By IPP Bureau - March 20, 2025
The new office in New Delhi marks a significant funding in the APAC region and reinforces the company’s commitment to advancing respiratory care in India
Croda opens advanced lipids manufacturing facility in Pennsylvania
By IPP Bureau - March 19, 2025
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
Financial Times names Indegene among high-growth companies in Asia-Pacific 2025
By IPP Bureau - March 19, 2025
Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products
Zydus receives final approval from USFDA for Apalutamide Tablets, 60 mg
By IPP Bureau - March 19, 2025
Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer
Anupriya Patel inaugurates India Innovation Summit – Pioneering Solutions to End TB
By IPP Bureau - March 19, 2025
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Clariant unveils natural preservation blend for cosmetics 'Nipaguard SCE Vita'
By IPP Bureau - March 19, 2025
Nipaguard SCE Vita delivers comprehensive antimicrobial protection for personal care formulations
Briefs: Zydus, Alkem Laboratories, Alkem Medtech and Relonchem
By IPP Bureau - March 19, 2025
Alkem Medtech to acquire 100% stake of Bombay Ortho
RedHill Biopharma to submit FDA-approved Talicia for UK marketing authorisation
By IPP Bureau - March 19, 2025
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
Shilpa Biologicals partners with mAbTree Biologics AG for a novel immunooncology asset
By IPP Bureau - March 18, 2025
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Lupin receives tentative approval from USFDA for Amifampridine Tablets
By IPP Bureau - March 18, 2025
Amifampridine Tablets, 10 mg are indicated for the treatment of Lambert-Eaton myasthenic syndrome in adults and pediatric patients 6 years of age and older.
Morepen launches Empamore for diabetes care with affordable treatment
By IPP Bureau - March 18, 2025
Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health
Dr. Reddy's issues nationwide recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL in US
By IPP Bureau - March 18, 2025
The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 m
CKD cases surge to 16.38% in Indians aged 15+
By IPP Bureau - March 17, 2025
Experts urge early detection & better access to care
Strides Pharma global to acquire 100% stake in Amextel
By IPP Bureau - March 17, 2025
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products
Zydus receives final approval from USFDA for Eluxadoline Tablets, 75 mg and 100 mg
By IPP Bureau - March 17, 2025
Eluxadoline is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhoea
